# Vero Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vero-biotech

- Industry: Biotechnology
- Headquarters: Atlanta, US
- Website: www.vero-biotech.com
- Total disclosed funding: $27M
- Latest round: Series E (Dec 8, 2021)
- Investors on record: 1

## About

Based in Georgia, US, and founded in 2006, Vero Biotech, Inc., a.k.a. Vero Biotech operates as a biotechnology company that focuses on design, development, and commercialization of inhaled nitric oxide (NO) delivery systems for patients with cardiopulmonary conditions. In February 2024, Vero Biotech, Inc. raised USD 65 million in venture debt funding from Horizon Technology Finance. As of July 2024, Brent Furse is the CEO of the company.

Vero Biotech provides inhaled nitric oxide delivery systems, focusing on the treatment of persistent pulmonary hypertension in newborns (PPHN). The company’s GENOSYL® Delivery System facilitates the administration of inhaled nitric oxide, which helps dilate pulmonary vasculature and improve oxygenation, reducing the need for extracorporeal membrane oxygenation (ECMO).

The company plans to use its proceeds from February 2024 funding to maintain the commercial growth of its research and development and Genosyl projects.

## Funding rounds

- Series E, Dec 8, 2021, $27M — MVM Partners

## Investors

- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series E